# [212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers

> **NCT06479811** · PHASE1 · RECRUITING · sponsor: **National Cancer Institute (NCI)** · enrollment: 120 (estimated)

## Conditions studied

- Head and Neck Tumors
- Kidney Cancers
- Small Cell Lung Cancers
- Pheochromocytoma/Paragangliomas
- Gastrointestinal Neuroendocrine Tumors
- Somatostatin Receptor Positive

## Interventions

- **DRUG:** 68Ga-DOTATATE
- **DRUG:** [203Pb]VMT-alpha-NET
- **DRUG:** [212Pb]VMT-alpha-NET

## Key facts

- **NCT ID:** NCT06479811
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-08-19
- **Primary completion:** 2029-01-01
- **Final completion:** 2032-01-01
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2026-04-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06479811

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06479811, "[212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06479811. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*